Table 4.
Adverse events with incidence ≥ 15% for all study subjects
| Adverse event | Emixustat (N = 12), n (%) | Placebo (N = 11), n (%) | All subjects, (N = 23), n (%) |
|---|---|---|---|
| Any adverse event | 12 (100) | 9 (81.8) | 21 (91.3) |
| Delayed dark adaptation | 9 (75.0) | 1 (9.1) | 10 (43.5) |
| Visual impairment | 6 (50.0) | 1 (9.1) | 7 (30.4) |
| Vision blurred | 1 (8.3) | 6 (54.5) | 7 (30.4) |
| Blindness day | 4 (33.3) | 3 (27.3) | 7 (30.4) |
| Vitreous floaters | 4 (33.3) | 2 (18.2) | 6 (26.1) |
| Visual acuity reduced | 4 (33.3) | 1 (9.1) | 5 (21.7) |
| Chromatopsia | 4 (33.3) | 0 | 4 (17.4) |
| Visual acuity tests abnormala | 2 (16.7) | 2 (18.2) | 4 (17.4) |
| Vitreous hemorrhage | 3 (25.0) | 1 (9.1) | 4 (17.4) |
aFor all 4 subjects, “visual acuity tests abnormal” refers to decreases in low-luminance best-corrected visual acuity